Precision Oncology News

Eli Lilly's Selpercatinib Shows Strong Activity in RET Fusion-Positive NSCLC

Sep 09, 2019

NEW YORK – In the Phase I/II LIBRETTO-001 study, 68 percent of 105 heavily pretreated non-small cell lung cancer patients with RET fusions saw their tumors shrink after treatment with Eli Lilly's investigational RET inhibitor selpercatinib, researchers reported today at the World Conference on Lung Cancer.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Eli Lilly's Selpercatinib Shows Strong Activity in RET Fusion-Positive NSCLC

To read the full story....

Breaking News

NCI Director Sharpless Outlines Ideas to Aggressively Lower Cancer Deaths at AACR Annual Meeting

AACR Study Tests Immunogenic Signature in Prostate Cancer Patients on Dual Checkpoint Inhibitor

Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute

Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

Portage Biotech Begins Phase I Trial of Invariant Natural Killer T-Cell Therapy

Featured White Papers

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

What's Popular?

In Brief This Week: Gilead Sciences, Atossa Therapeutics, Karmanos Cancer Institute

Immunocore's Tebentafusp Prolongs Survival in Uveal Melanoma Patients, AACR Study Shows

Celcuity Licenses PI3K/mTOR Inhibitor from Pfizer, Enters $25M Debt Financing Agreement

With Support From Lawmakers, WGS Becoming More Accessible to Netherlands' Cancer Patients

Gene Expression Score IDs PD-1/PD-L1 Immune Checkpoint Inhibitor Resistance in Bladder Cancers

Sponsorships